Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma
The Oncologist · 01.10.2025 · 30 (10)
DOI: 10.1093/oncolo/oyaf220 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.11.2025. Verfasst von Syed Hussain und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Population Health, Department of Oncology, University of Sheffield, Sheffield S10 2SJ, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Ltd.
Abstract (Originalsprache)
Prescribing information & ADR reporting This is an Astellas article. Prescribing information can be accessed at https://dhgd52pup2eiv.cloudfront.net/23ffe42b-4e89-48e1-b8d8-08b726ed94c1/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb/b5d6cdf5-d05a-4bb1-9965-de9a244d39eb_source__v.pdf and the adverse event reporting information can be found on the last page of that link.
Background
Advanced urothelial carcinoma (UC) significantly impacts quality of life, is associated with poor prognosis, and carries a high economic burden. Recently, the combination of enfortumab vedotin and pembrolizumab (EV-P) has demonstrated improved progression-free survival vs platinum-based chemotherapy and overall survival, and is now recommended as a first-line therapy for patients with unresectable or metastatic disease who are platinum eligible.
Methods
A multidisciplinary expert panel was convened to review the current UK patient pathway for advanced UC. The panel developed consensus recommendations for implementing EV-P in the United Kingdom and provided guidance on managing adverse events (AEs), taking into account the challenges in the current pathway.
Results
The expert panel recommended leveraging lessons from the previous implementation of new immunotherapies and antibody-drug conjugates as EV-P is implemented across the United Kingdom. They emphasized the importance of peer support from clinical centers involved in the EV-302 phase 3 clinical trial, advocating for the sharing of protocols, advice, and support for toxicity management. Recommendations included establishing robust referral pathways and multidisciplinary care models tailored to the resources and structures of different hospital settings. Education in proactive side effect identification and management was recommended for bladder cancer clinical nurse specialists, acute oncology nurses, pharmacists, and clinicians. The panel developed patient checklists to support clinicians in assessing treatment suitability, monitoring AEs during therapy, and ensuring continued monitoring after treatment ends. Detailed recommendations were provided for managing AEs, with a focus on skin reactions, peripheral neuropathy, hyperglycemia, pneumonitis/interstitial lung disease, and ocular disorders, along with guidance on when to involve specialist services.
Conclusion
These consensus recommendations provide practical, multidisciplinary guidance to support the effective implementation of EV-P for advanced UC in UK healthcare settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Population Health, Department of Oncology, University of Sheffield, Sheffield S10 2SJ, United Kingdom.
- School of Cancer Sciences, University Hospital Southampton NHS Foundation Trust, Southampton SO17 1BJ, United Kingdom.
- National Hospital for Neurology and Neurosurgery (NHNN), University College London Hospitals NHS Trust, London W1T 4JD, United Kingdom.
- Mount Vernon Cancer Centre , East and North Hertfordshire NHS Trust, Northwood WD3 1PZ, United Kingdom.
- Department of Dermatology, Chelsea and Westminster NHS Hospital Trust, London SW10 9NH, United Kingdom.
- Edinburgh Cancer Centre, NHS Lothian, Edinburgh EH4 2XU, United Kingdom.
ORCID-Profile: Syed Hussain
Förderung
- Astellas Pharma Ltd
Zitieren
APA
Hussain, S., Carr, A., Crabb, S. J., Dodhia, V., Fearfield, L., Malik, J. M., Lapuente, M., Lau, D., Petruskin, H., Sarwar, N., Smith, N. J., Stevenson, R., & Jones, R. (2025). Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma. The Oncologist, 30(10). https://doi.org/10.1093/oncolo/oyaf220
Vancouver
Hussain S, Carr A, Crabb SJ, Dodhia V, Fearfield L, Malik JM, et al. Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma. The Oncologist. 2025;30(10). doi:10.1093/oncolo/oyaf220
BibTeX
@article{Hussain2025,
author = {Hussain, Syed and Carr, Aisling and Crabb, Simon John and Dodhia, Vikash and Fearfield, Louise and Malik, Jahangeer Mahmood and Lapuente, Maria and Lau, Davina and Petruskin, Harry and Sarwar, Naveed and Smith, Nicola Jane and Stevenson, Robert and Jones, Robert},
title = {Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {10},
doi = {10.1093/oncolo/oyaf220}
}
EUVIMED